

François Mullier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/932000/publications.pdf>

Version: 2024-02-01

169
papers

12,900
citations

66336

42
h-index

25787

108
g-index

180
all docs

180
docs citations

180
times ranked

18782
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535750.	12.2	6,961
2	Impact of dabigatran on a large panel of routine or specific coagulation assays. <i>Thrombosis and Haemostasis</i> , 2012, 107, 985-997.	3.4	321
3	EVpedia: a community web portal for extracellular vesicles research. <i>Bioinformatics</i> , 2015, 31, 933-939.	4.1	317
4	Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1190-1193.	3.8	287
5	Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 209-219.	3.8	266
6	Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature. <i>Thrombosis Research</i> , 2012, 130, 956-966.	1.7	201
7	Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. <i>Thrombosis and Haemostasis</i> , 2013, 110, 283-294.	3.4	179
8	Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival. <i>JAMA Oncology</i> , 2016, 2, 625.	7.1	158
9	Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2013, 110, 723-731.	3.4	141
10	Antibody titres decline 3-month post-vaccination with BNT162b2. <i>Emerging Microbes and Infections</i> , 2021, 10, 1495-1498.	6.5	141
11	Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1236-1245.	3.8	130
12	Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. <i>Critical Care</i> , 2020, 24, 364.	5.8	118
13	D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 548-577.	6.1	116
14	Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. <i>European Heart Journal</i> , 2017, 38, 2431-2439.	2.2	106
15	Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. <i>Vaccines</i> , 2021, 9, 1092.	4.4	96
16	Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2013, 110, 543-549.	3.4	92
17	Perioperative management of patients on direct oral anticoagulants. <i>Thrombosis Journal</i> , 2017, 15, 14.	2.1	92
18	Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories. <i>Thrombosis Journal</i> , 2016, 14, 49.	2.1	88

#	ARTICLE	IF	CITATIONS
19	Dabigatran Etxilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2014, 3, e000515.	3.7	85
20	Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. <i>European Journal of Haematology</i> , 2015, 95, 190-198.	2.2	85
21	Appropriateness of Prescribing Dabigatran Etxilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1258-1268.	1.9	81
22	Characterisation of tissue factor-bearing extracellular vesicles with AFM: comparison of air-tapping mode AFM and liquid Peak Force AFM. <i>Journal of Extracellular Vesicles</i> , 2013, 2, .	12.2	74
23	Influence of dabigatran and rivaroxaban on routine coagulation assays. <i>Thrombosis and Haemostasis</i> , 2015, 113, 154-164.	3.4	73
24	Impact of Silver Nanoparticles on Haemolysis, Platelet Function and Coagulation. <i>Nanobiomedicine</i> , 2014, 1, 4.	5.7	67
25	Tips and tricks for flow cytometry-based analysis and counting of microparticles. <i>Transfusion and Apheresis Science</i> , 2015, 53, 110-126.	1.0	67
26	Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. <i>Thrombosis Journal</i> , 2018, 16, 28.	2.1	63
27	Edoxaban: Impact on routine and specific coagulation assays. <i>Thrombosis and Haemostasis</i> , 2016, 115, 368-381.	3.4	61
28	Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review. <i>Molecules</i> , 2017, 22, 617.	3.8	61
29	Pre-analytical issues in the measurement of circulating microparticles: current recommendations and pending questions. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 693-696.	3.8	59
30	Additional erythrocytic and reticulocytic parameters helpful for diagnosis of hereditary spherocytosis: results of a multicentre study. <i>Annals of Hematology</i> , 2011, 90, 759-768.	1.8	55
31	Evaluation of the DOAC-Stop [®] Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests. <i>TH Open</i> , 2018, 02, e202-e209.	1.4	54
32	Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. <i>Chest</i> , 2021, 159, 2417-2427.	0.8	54
33	Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). <i>Clinical Microbiology and Infection</i> , 2021, 27, 1351.e5-1351.e7.	6.0	54
34	Estimation of dabigatran plasma concentrations in the perioperative setting. <i>Thrombosis and Haemostasis</i> , 2015, 113, 862-869.	3.4	53
35	Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. <i>Thrombosis Journal</i> , 2020, 18, 17.	2.1	52
36	Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. <i>Thrombosis Research</i> , 2021, 203, 163-171.	1.7	52

#	ARTICLE	IF	CITATIONS
37	More on: calibration for the measurement of microparticles: needs, interests, and limitations of calibrated polystyrene beads for flow cytometry-based quantification of biological microparticles. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1679-1681.	3.8	51
38	Heparin-induced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2548-2552.	3.8	48
39	Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 5-12.	2.4	48
40	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. <i>Thrombosis Journal</i> , 2014, 12, 24.	2.1	45
41	Diagnosis and management of heparin-induced thrombocytopenia. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 291-310.	1.4	45
42	Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant. <i>Viruses</i> , 2022, 14, 654.	3.3	44
43	Assessment of the analytical performances and sample stability on ST Genesia system using the STG DrugScreen application. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1273-1287.	3.8	43
44	Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1740.	2.4	43
45	NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. <i>Frontiers in Pharmacology</i> , 2021, 12, 708302.	3.5	37
46	Platelet microparticle generation assay: A valuable test for immune heparin-induced thrombocytopenia diagnosis. <i>Thrombosis Research</i> , 2014, 133, 1068-1073.	1.7	36
47	Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. <i>Thrombosis Research</i> , 2021, 197, 20-23.	1.7	36
48	Microparticle bearing tissue factor: A link between promyelocytic cells and hypercoagulable state. <i>Thrombosis Research</i> , 2014, 133, 433-439.	1.7	35
49	Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. <i>BioMed Research International</i> , 2015, 2015, 1-13.	1.9	35
50	Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2020, 9, 1226.	2.4	34
51	Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2. <i>Microorganisms</i> , 2021, 9, 1340.	3.6	33
52	Advances in Platelet Function Testing—Light Transmission Aggregometry and Beyond. <i>Journal of Clinical Medicine</i> , 2020, 9, 2636.	2.4	31
53	Comparison of five D-dimer reagents and application of an age-adjusted cut-off for the diagnosis of venous thromboembolism in emergency department. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 309-315.	1.0	30
54	Usefulness of Flow Cytometric Mepacrine Uptake/Release Combined with CD63 Assay in Diagnosis of Patients with Suspected Platelet Dense Granule Disorder. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 282-291.	2.7	30

#	ARTICLE	IF	CITATIONS
55	Pseudothrombocytopenia "A Review on Causes, Occurrence and Clinical Implications. Journal of Clinical Medicine, 2021, 10, 594.	2.4	29
56	Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. Thrombosis Research, 2015, 136, 693-696.	1.7	28
57	Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thrombosis Research, 2015, 135, 852-860.	1.7	26
58	Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: A retrospective study. Thrombosis Research, 2013, 132, 352-359.	1.7	25
59	Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. Thrombosis Research, 2017, 156, 36-38.	1.7	25
60	Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 379-389.	1.4	25
61	Validation of the calibrated thrombin generation test (cTGT) as the reference assay to evaluate the procoagulant activity of nanomaterials. Nanotoxicology, 2012, 6, 213-232.	3.0	24
62	Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles. Journal of Extracellular Vesicles, 2013, 2, 19728.	12.2	24
63	Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme. International Journal of Laboratory Hematology, 2017, 39, 402-408.	1.3	24
64	Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. BioMed Research International, 2014, 2014, 1-16.	1.9	23
65	Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry. Thrombosis Research, 2014, 133, 1074-1078.	1.7	23
66	Evaluation of the Fully Automated HemosIL Acustar ADAMTS13 Activity Assay. Thrombosis and Haemostasis, 2018, 118, 942-944.	3.4	23
67	Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory. International Journal of Laboratory Hematology, 2021, 43, 7-20.	1.3	23
68	Contribution of platelet microparticles generation assay to the diagnosis of type II heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2010, 103, 1277-1281.	3.4	22
69	A CEIL flow cytometry consensus proposal for quantification of plasma cells: Application to differential diagnosis between MGUS and myeloma. Cytometry Part B - Clinical Cytometry, 2011, 80B, 176-185.	1.5	22
70	Dose tailoring of dabigatran etexilate: obvious or excessive?. Expert Opinion on Drug Safety, 2015, 14, 1283-1289.	2.4	22
71	Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). Archives of Cardiovascular Diseases, 2018, 111, 210-223.	1.6	22
72	Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 129-138.	1.7	22

#	ARTICLE	IF	CITATIONS
73	Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 224-232.	2.1	21
74	BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?. <i>TH Open</i> , 2018, 02, e68-e88.	1.4	21
75	The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation. <i>Thrombosis Research</i> , 2018, 171, 160-166.	1.7	21
76	Betrixaban: Impact on Routine and Specific Coagulation Assays – A Practical Laboratory Guide. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1203-1214.	3.4	21
77	Extracellular Vesicles in Red Blood Cell Concentrates: An Overview. <i>Transfusion Medicine Reviews</i> , 2019, 33, 125-130.	2.0	21
78	Post-SARS-CoV-2 vaccination specific antibody decrease – Thresholds for determining seroprevalence and seroneutralization differ. <i>Journal of Infection</i> , 2021, 83, e4-e5.	3.3	20
79	Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data. <i>Data in Brief</i> , 2020, 33, 106519.	1.0	19
80	Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter study. <i>Annals of Hematology</i> , 2012, 91, 203-213.	1.8	18
81	Remodeling and Repair in Rhinosinusitis. <i>Current Allergy and Asthma Reports</i> , 2015, 15, 34.	5.3	17
82	Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 41-50.	11.4	17
83	Effects of Time-Interval since Blood Draw and of Anticoagulation on Platelet Testing (Count, Indices) Tj ETQq1 1 0.784314 rgBT /Over Clinical Medicine, 2020, 9, 2515.	2.4	17
84	D-dimer: old dogmas, new (COVID-19) tricks. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 841-850.	2.3	17
85	Inhibition of tissue factor pathway inhibitor increases the sensitivity of thrombin generation assay to procoagulant microvesicles. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 567-572.	1.0	16
86	Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance, and their limitations. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3121-3124.	3.8	16
87	The Impact of Strong Inducers on Direct Oral Anticoagulant Levels. <i>American Journal of Medicine</i> , 2021, 134, 1295-1299.	1.5	16
88	Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COVS.2.S: first documented case outside US. <i>Infection</i> , 2022, 50, 531-536.	4.7	16
89	Impact of the Direct Oral Anticoagulants on Activated Clotting Time. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, e24-e27.	1.3	15
90	European guidelines on perioperative venous thromboembolism prophylaxis. <i>European Journal of Anaesthesiology</i> , 2018, 35, 96-107.	1.7	15

#	ARTICLE	IF	CITATIONS
91	The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review. <i>Journal of Extracellular Vesicles</i> , 2014, 3, .	12.2	14
92	Deficiency in mouse hyaluronidase 2: a new mechanism of chronic thrombotic microangiopathy. <i>Haematologica</i> , 2015, 100, 1023-30.	3.5	14
93	An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. <i>Thrombosis Research</i> , 2017, 157, 29-37.	1.7	14
94	A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN TM analyzers in routine laboratory practice. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 159-164.	1.2	14
95	The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs. <i>Thrombosis Research</i> , 2018, 168, 63-66.	1.7	14
96	Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2526-2529.	3.8	14
97	Heparin-induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1959-1972.	3.8	14
98	The Effect of Clonidine, an Alpha-2 Adrenergic Receptor Agonist, on Inflammatory Response and Postischemic Endothelium Function During Early Reperfusion in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 60, 553-560.	1.9	13
99	Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer. <i>Journal of Extracellular Vesicles</i> , 2014, 3, .	12.2	13
100	Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021). <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100919.	1.4	12
101	A comparison of six major platelet functional tests to assess the impact of carbon nanomaterials on platelet function: A practical guide. <i>Nanotoxicology</i> , 2014, 8, 220-232.	3.0	11
102	Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e48-e51.	1.3	11
103	Bioactivity and hemocompatibility study of amorphous hydrogenated carbon coatings produced by pulsed magnetron discharge. <i>Journal of Biomedical Materials Research - Part A</i> , 2013, 101A, 1800-1812.	4.0	10
104	Persistent heparin-induced thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 193-197.	1.0	10
105	Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1275-1296.	3.1	10
106	Reduction of the turnaround time for the measurement of rivaroxaban and apixaban: Assessment of the performance of a rapid centrifugation method. <i>International Journal of Laboratory Hematology</i> , 2018, 40, e105-e108.	1.3	10
107	Toward standardization of assays measuring extracellular vesicle-associated tissue factor activity. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1261-1264.	3.8	10
108	Andexanet alfa for the reversal of factor Xa inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 387-397.	3.1	10

#	ARTICLE	IF	CITATIONS
109	Evaluation and optimization of the <i>E</i>-IPU) validation module integrating the sysmex flag systems and the recommendations of the French-speaking cellular hematology group (GFHC). Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 465-471.	1.2	9
110	Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio" results before/after extraction with the DOAC Stop reagent. Thrombosis Research, 2019, 179, 69-72.	1.7	9
111	Optimal wavelength for the clot waveform analysis: Determination of the best resolution with minimal interference of the reagents. International Journal of Laboratory Hematology, 2019, 41, 316-324.	1.3	9
112	Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. International Journal of Laboratory Hematology, 2019, 41, 250-261.	1.3	9
113	Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. Cancers, 2020, 12, 1242.	3.7	9
114	Analytical and clinical evaluation of four commercial SARS-CoV-2 serological immunoassays in hospitalized patients and ambulatory individuals. Journal of Virological Methods, 2021, 289, 114060.	2.1	9
115	Could Daily Monitoring of Fibrin Related Markers Help Suspect a Thrombotic Event in COVID-19 Patients? A Prospective Pilot Study. TH Open, 2021, 05, e152-e154.	1.4	9
116	Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rationale for monitoring immunoglobulin G levels. Haematologica, 2021, 106, 3249-3252.	3.5	9
117	Expression of a Schistosoma mansoni 28-kilodalton glutathione S-transferase in the livers of transgenic mice and its effect on parasite infection. Infection and Immunity, 1997, 65, 3867-3874.	2.2	9
118	A Case of Therapy-Related Myeloid Neoplasm in a Patient with Crohn's Disease Treated with Azathioprine. Acta Haematologica, 2012, 128, 1-6.	1.4	8
119	Erratum to "Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants". BioMed Research International, 2014, 2014, 1-1.	1.9	8
120	Study of in vitro thrombin generation after neutralization of heparin. International Journal of Laboratory Hematology, 2022, 44, 168-176.	1.3	8
121	Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thrombosis Research, 2017, 156, 142-148.	1.7	7
122	Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants. BioMed Research International, 2014, 2014, 1-14.	1.9	6
123	Platelet microparticle generation assay for heparin-induced thrombocytopenia diagnosis: How should we express the results?. Thrombosis Research, 2015, 136, 175-177.	1.7	6
124	Evaluation of a hereditary spherocytosis screening algorithm by automated blood count using reticulocytes and erythrocytic parameters on the Sysmex XN series. International Journal of Laboratory Hematology, 2020, 42, e88-e91.	1.3	6
125	Two-site evaluation of a new workflow for the detection of malignant cells on the Sysmex XN-1000 body fluid analyzer. International Journal of Laboratory Hematology, 2020, 42, 544-551.	1.3	6
126	Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study. Thrombosis Research, 2021, 205, 8-10.	1.7	6

#	ARTICLE	IF	CITATIONS
127	Evaluation of a new thromboplastin reagent STA [®] NeoPTimal on a STA R Max analyzer for the measurement of prothrombin time, international normalized ratio and extrinsic factor levels. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 650-660.	1.3	6
128	Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory Tests. <i>Regional Anesthesia and Pain Medicine</i> , 2016, 41, 787-788.	2.3	5
129	Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants. <i>Thrombosis Research</i> , 2020, 185, 72-77.	1.7	5
130	Assessment of low plasma concentrations of apixaban in the periprocedural setting. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 394-402.	1.3	5
131	Multicentre evaluation of 5B9, a monoclonal anti [®] PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 252-259.	3.8	5
132	Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19 [®] BNT162b2 mRNA Vaccination. <i>Viruses</i> , 2022, 14, 1470.	3.3	5
133	No effect of lysis solutions on absolute CD19+ lymphocytes count and CD45 index in chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 369-372.	1.5	4
134	Heparin monitoring: clinical outcome and practical approach. <i>Annales De Biologie Clinique</i> , 2016, 74, 637-652.	0.1	4
135	Usefulness of thresholds for smear review of neutropenic samples analyzed with a Sysmex XN-10 analyzer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 406-409.	1.2	4
136	Development and validation of a liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of serotonin and thromboxane B2 from activated platelets. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 663-671.	1.3	4
137	Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation. <i>Thrombosis Research</i> , 2019, 184, 8-15.	1.7	4
138	Utility of the XN [®] 1000 research mode for leukocytes counting in ascitic and pleural fluids. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e92-e95.	1.3	4
139	Reduction of Preoperative Waiting Time Before Urgent Surgery for Patients on P2Y12 Inhibitors Using Multiple Electrode Aggregometry: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 424.	2.4	4
140	Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. <i>Blood Transfusion</i> , 2018, 16, 163-172.	0.4	4
141	Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement. <i>Journal of Clinical Medicine</i> , 2022, 11, 1338.	2.4	4
142	DEFINITION OF CLINICAL THRESHOLD FOR CMV REAL-TIME PCR AFTER COMPARISON WITH PP65 ANTIGENAEMIA AND CLINICAL DATA. <i>Acta Clinica Belgica</i> , 2009, 64, 477-482.	1.2	3
143	Microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. <i>Thrombosis Research</i> , 2014, 134, 213-214.	1.7	3
144	Real-world variability in dabigatran levels in patients with atrial fibrillation: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1166-1168.	3.8	3

#	ARTICLE	IF	CITATIONS
145	Inappropriate low dosing of direct oral anticoagulants in older patients with non-valvular atrial fibrillation: Impact on plasma drug levels. <i>Thrombosis Research</i> , 2021, 201, 139-142.	1.7	3
146	Don't let D-dimer fool you: Elevated D-dimer plasma levels should not imply "hyperfibrinolysis". <i>Thrombosis Research</i> , 2022, 214, 63-64.	1.7	3
147	A reminder of the place of morphology and the H&E score in the diagnosis of hemophagocytic lymphohistiocytosis (<scp>HLH</scp>). <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 527-528.	0.5	2
148	Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab. <i>Medicine (United States)</i> , 2019, 98, e16164.	1.0	2
149	Measurement of factor VIII activity of efralotocog alfa with commercially available one–stage clotting and chromogenic assays: Results from the Belgian national External Quality Assessment Scheme. <i>International Journal of Laboratory Hematology</i> , 2019, 41, e20-e22.	1.3	2
150	Concentrations of direct oral anticoagulants according to guidelines for the periprocedural management of low bleeding risk procedures. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 121-122.	1.4	2
151	Impact of centrifugation on thrombin generation in healthy subjects and in patients treated with direct oral anticoagulants. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1585-1592.	1.3	2
152	The euglobulin clot lysis time to assess the impact of nanoparticles on fibrinolysis. <i>Journal of Nanoparticle Research</i> , 2015, 17, 1.	1.9	1
153	Criteria for Prescribing Dabigatran Etxilate and Rivaroxaban Really Appropriate? Authors–Reply. <i>Annals of Pharmacotherapy</i> , 2015, 49, 155-155.	1.9	1
154	Influence of C-reactive protein on thrombin generation assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e301-e305.	2.3	1
155	Estimation of Dabigatran Plasma Concentrations in the Perioperative Setting. an Ex-Vivo Study Using Dedicated Coagulation Assays. <i>Blood</i> , 2014, 124, 1549-1549.	1.4	1
156	Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 864899.	2.4	1
157	The edoxaban–M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12680.	2.3	1
158	Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rationale for monitoring immunoglobulin G levels. <i>Haematologica</i> , 2021, , .	3.5	1
159	Apports de–cytologie et–cytom–trie en–flux dans–le–diagnostic d'un lymphome T angio-immunoblastique (LTAI) avec–envahissement sanguin et–dullaire: cas clinique et–revue de–lit–ature. <i>Hematologie</i> , 2009, 15, 314-318.	0.0	0
160	From XE-2100 to XN-9000, from SIS Standard to GFHC recommendations for slide review: potential impact on review rate and turnaround time. <i>Annales De Biologie Clinique</i> , 2017, 75, 285-292.	0.1	0
161	Position du GH–P sur les tests visco–plastiques–: quelle place pour quelle indication en situation h–morragique–. <i>Anesth&#x2013;sie & R&#x2013;animation</i> , 2018, 4, 452-464.	0.1	0
162	Two-site evaluation of high-fluorescent cells for the detection of malignant cells: The importance of clinical information. <i>Clinica Chimica Acta</i> , 2019, 493, S428-S429.	1.1	0

#	ARTICLE	IF	CITATIONS
163	Comparison is not reason: Pitfalls in reporting thrombin generation results in anticoagulated patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12523.	2.3	0
164	Prothrombotic Disturbances of Hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational Study. , 2021, 41, .		0
165	Is Dilute Russell's Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etxilate?. <i>Blood</i> , 2013, 122, 3634-3634.	1.4	0
166	Dabigatran Etxilate and Risk Of Myocardial Infarction, Major Bleeding and All-Cause Mortality: A Systematic Review and Meta-Analysis Of Randomized Controlled Trials. <i>Blood</i> , 2013, 122, 3633-3633.	1.4	0
167	Is Thrombin Time Useful To Guide Peri-Procedural Management For Patients On Dabigatran Etxilate?: An In Vitro Validation Study. <i>Blood</i> , 2013, 122, 2388-2388.	1.4	0
168	Clustering and Kernel Density Estimation for Assessment of Measurable Residual Disease by Flow Cytometry. <i>Diagnostics</i> , 2020, 10, 317.	2.6	0
169	Effect of tissue factor pathway inhibitor on thrombin generation assay. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	1.3	0